Target: Hypertension
From "
"
Impaired coronary blood flow in prehypertension
Learning objectives
Discuss the impact of impaired coronary flow reserve among normotensive, prehypertensive, and newly diagnosed and never-treated subjects with established hypertension.
Questions
- The 150 subjects enrolled in the Erdogan study were divided into 3 groups according to their blood pressure: normotensive, hypertensive, and prehypertensive. Analysis of echocardiographic measurements showed that all but which of the following were similar in all 3 groups. Ejection fraction Left ventricular posterior wall thickness Left ventricular mass index End-diastolic diameter
- Abnormal coronary flow reserve (CFR) was found in _____ of subjects with hypertension, whereas all the normotensive subjects had normal CFR. 20% 35% 40% 45%
- _____ was slightly lower in the prehypertensive group compared with the normotensive group and significantly lower in the hypertensive group. The high-sensitivity C-reactive protein (hs-CRP) level Mitral E deceleration time Left ventricular mass index Hyperemic diastolic peak flow velocity (DPFV)
- It has been shown that prehypertension is associated with a ____ increase in all-cause mortality and a 66% increase in cardiovascular mortality. 27% 32% 45% 56%
- Coronary flow reserve measured by transthoracic Doppler echocardiography (TTDE) has recently been shown to have an excellent correlation with CFR measured by ________, which has been validated as the gold standard for CFR measurement. intravascular ultrasound single-photon emission computed tomography (CT) coronary CT angiography positron emission tomography
To take this exam, you can
. Cardiology Review materials are posted to that site on a continuous basis (registration required).
download the CME answer form (PDF) and mail, fax, or email it to address given; or go to the University of Cincinnati's Center for Continuous Professional Development
Target: CAD and Diabetes
From "
"
Pioglitazone and recurrent MI in patients with diabetes and a previous MI
Learning objectives
Describe the effects of pioglitazone on mortality and macrovascular morbidity among subjects with diabetes, macrovascular disease, and previous myocardial infarction.
Questions
- Pioglitazone improves glycemic control, increases high-density lipoprotein (HDL) cholesterol, and lowers low-density lipoprotein (LDL) cholesterol and triglycerides. It has also been shown to reduce ________, a marker of cardiovascular risk in patients with type 2 diabetes. high-sensitivity C-reactive protein (hs-CPR) levels elevated serum prolactin levels the progression of carotid intima media thickness body mass index
- The use of pioglitazone in the PROactive study decreased the occurrence of acute coronary syndrome by ____. 19% 28% 37% 42%
- The results of the multivariate analysis of 25 baseline characteristics showed that __________ was a negative predictor of a second MI. increased LDL-cholesterol level increased insulin use prior revascularization increased age
- The American Heart Association (AHA) and the American Diabetes Association has issued guidelines for the use of thiazolidinediones in patients with type 2 diabetes and heart failure. The guidelines recommend that thiazolidinedione treatment should be initiated in patients with heart failure with the lowest possible dose, followed by slow dose escalation based on _______. fasting plasma glucose (FPG) levels glycosylated hemoglobin levels hs-CRP levels IGF-2 levels
- The results of the subgroup analysis showed that pioglitazone was more effective in preventing MI than placebo. Treating 1000 patients with type 2 diabetes with pioglitazone in addition to their existing on-going medications would avoid ____ recurrent MIs over a 3-year follow-up period. 5 11 16 22
To take this exam, you can
. Cardiology Review materials are posted to that site on a continuous basis (registration required).
download the CME answer form (PDF) and mail, fax, or email it to address given; or go to the University of Cincinnati's Center for Continuous Professional Development